DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
Acknowledgement is made of Applicant’s claim of the present application being a continuation of U.S. Patent Application No. 18/088,110, filed December 23, 2022, which is a division of U.S. Patent Application No. 17/344,505, filed June 10, 2021, now issued as U.S. Patent No. 11,661,619, which is a continuation application of U.S. Patent Application No. 16/773,535, filed January 27, 2020, now issued as U.S. Patent No. 11, 066,689, which is a continuation application of U.S. Patent Application No. 15/532,428, filed June 1, 2017, now issued as U.S. Patent No. 10,584,366, which is a National Stage Application, filed under 35 U.S.C §371, of International Application No. PCT/US2015/063754 filed December 3, 2015, which claims the benefit of priority to U.S. Provisional Patent Application Serial No. 62/087,147 filed December 3, 2014.
Information Disclosure Statement
The information disclosure statements (“IDS”) filed on 05/20/2025 (five sets) were reviewed and the listed references were noted.
Drawings
The 39-page drawings have been considered and placed on record in the file.
Status of Claims
Claims 11-27 are pending. Claims 1-10 are canceled.
Claim Interpretation
The following is a quotation of 35 U.S.C. 112(f):
(f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof.
The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph:
An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof.
Use of the word “means” (or “step for”) in a claim with functional language creates a rebuttable presumption that the claim element is to be treated in accordance with 35 U.S.C. 112(f) (pre-AIA 35 U.S.C. 112, sixth paragraph). The presumption that 35 U.S.C. 112(f) (pre-AIA 35 U.S.C. 112, sixth paragraph) is invoked is rebutted when the function is recited with sufficient structure, material, or acts within the claim itself to entirely perform the recited function.
Absence of the word “means” (or “step for”) in a claim creates a rebuttable presumption that the claim element is not to be treated in accordance with 35 U.S.C. 112(f) (pre-AIA 35 U.S.C. 112, sixth paragraph). The presumption that 35 U.S.C. 112(f) (pre-AIA 35 U.S.C. 112, sixth paragraph) is not invoked is rebutted when the claim element recites function but fails to recite sufficiently definite structure, material or acts to perform that function.
Claim elements in this application that use the word “means” (or “step for”) are presumed to invoke 35 U.S.C. 112(f) except as otherwise indicated in an Office action. Similarly, claim elements that do not use the word “means” (or “step for”) are presumed not to invoke 35 U.S.C. 112(f) except as otherwise indicated in an Office action.
The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked.
As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph:
(A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function;
(B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and
(C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function.
Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function.
Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function.
Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action.
This application includes one or more claim limitations that do not use the word “means,” but are nonetheless being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation is: “an imaging apparatus that generates …” in Claim 11.
Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof.
If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper time-wise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.
Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). In order to expedite the processing/approval of the terminal disclaimer, Applicants may choose to file an electronic terminal disclaimer (eTerminal Disclaimer) by referring to the following website:
http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp
Claims 11-27 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims of parent Patent Nos. 11,066,689 and 10,584,366. Although the claims at issue are not identical, they are not patentably distinct from each other, because the claims of the instant application are broader in every aspect than the claims in the parent patent, and are therefore, obvious variants thereof. For example, the following chart compares independent Claim 11 of the instant application and Claim 1 of the parent Patent No. 11,066,689.
Instant Application
Patent Application No. 11,066,689
Claim 11. A system for discretely resolving analytes associated with a cellular population comprising:
a plurality of sample retention regions that receive at least one cell distributed from a population of cells and retain an associated plurality of analytes released by the at least one cell;
a plurality of analyte detection regions patterned with a plurality of discretely positioned analyte detection moieties, the analyte detection regions disposed in an ordered pattern alignable with the sample retention regions whereby, upon coupling, released analytes selectively associate with the plurality of analyte detection moieties forming an analyte pattern for each analyte detection region;
a plurality of first alignment markers disposed about the plurality of sample retention regions and a plurality of second alignment markers disposed about the plurality of analyte detection regions;
an imaging apparatus that generates:
a plurality of first images for selected sample retention regions and retained at least one cell and additionally at least one first alignment marker, and
a plurality of second images having a different optical parameter than the first images, the second images for analyte detection regions corresponding to the selected sample regions and associated analyte patterns and additionally at least one second alignment marker; and
an image processor that aligns associated images for selected sample retention regions using the at least one first alignment marker and further aligns images for analyte detection regions with corresponding images for selected sample retention regions using the at least one second alignment marker, the image processor further identifying retained at least one cell in respective sample retention regions and corresponding analyte patterns to discretely resolve released analytes associated with retained at least one cell based on the analyte detection moieties detected in the analyte pattern.
Claim 1. A system for discretely resolving analytes associated with a cellular population comprising:
a plurality of sample retention regions that receive at least one cell distributed from a population of cells and retain an associated plurality of analytes released by the at least one cell;
a plurality of analyte detection regions patterned with a plurality of discretely positioned analyte detection moieties, the analyte detection regions disposed along parallel lines forming a barcode pattern alignable with the sample retention regions whereby, upon coupling, released analytes selectively associate with the plurality of analyte detection moieties forming an analyte barcode pattern for each analyte detection region;
a plurality of first alignment markers disposed about the plurality of sample retention regions and a plurality of second alignment markers disposed about the plurality of analyte detection regions;
an imaging apparatus that generates a plurality of images for selected sample retention regions and retained at least one cell and additionally at least one first alignment marker, the imaging apparatus further generating a plurality of images for analyte detection regions corresponding to the selected sample regions and associated analyte barcode patterns and additionally at least one second alignment marker;
and an image processor that aligns associated images for selected sample retention regions using the at least one first alignment marker and further aligns images for analyte
detection regions with corresponding images for selected sample retention regions using the at least one second alignment marker, the image processor further identifying retained at least one cell in respective sample retention regions and corresponding analyte barcode patterns to discretely resolve released analytes associated with the retained at least one cell based on the analyte detection moieties detected in the analyte barcode pattern.
Allowable Subject Matter
Claims 11-27 are not rejected over prior art and will be allowed once the above-described rejection based on non-statutory double patenting is overcome. The following is Examiner’s stated reasons for the allowable subject matter: consider Claim 11, Lu et al. (“High-Throughput Secretomic Analysis of Single Cells to Assess Functional Cellular Heterogeneity”) discloses “A system for discretely resolving analytes associated with a cellular population comprising:
a plurality of sample retention regions that receive at least one cell distributed from a population of cells and retain an associated plurality of analytes released by the at least one cell” (Page 10, Fig. 1a, a plurality of sample retention regions corresponds to the plurality rectangular regions within the element (1) sub-nanoliter micro chamber array, which receives at least one cell distributed from a population of cells and retain an associated plurality of analytes released by the at least one cell);
“a plurality of analyte detection regions patterned with a plurality of discretely positioned analyte detection moieties, the analyte detection regions disposed in an ordered pattern alignable with the sample retention regions whereby, upon coupling, released analytes selectively associate with the plurality of analyte detection moieties forming an analyte pattern for each analyte detection region” (Page 10, Fig. 1a, shows the protein secretion, which corresponds to the analyte detection moieties, and the plurality of analyte detection regions [i.e., the aligned colors], are shown within the element ((2) ultra-high density antibody barcodes) of Fig. 1a, and are pattern and associated with the plurality of discretely positioned protein secretion, [e.g., the plurality of aligned colors within the small rectangle], forming an analyte pattern);
a plurality of first alignment markers disposed about the plurality of sample retention regions and a plurality of second alignment markers disposed about the plurality of analyte detection regions” (Right hand of Fig. 1a, as shown in the element “5440 microchambers+14-pixeled protein secretion assay at the level of single cells” of Fig. 1a, a plurality of alignment markers disposed about the plurality of sample retention regions of said element (1) sub-nanoliter micro chamber array);
an imaging apparatus that generates: a plurality of images for selected sample retention regions and retained at least one cell and additionally at least one first alignment marker” (Page 12, see Fig. 3, generating representative region of the scanned image showing the raw data of single cell Secretomic measurement…..24h), [i.e., plurality of images for selected sample retention regions and retained at least one cell]. Further, Page 4, Subsection: Single-cell Protein secretomic analysis on cell lines” left-hand-column, first paragraph, “As shown in a representative region of the scanned fluorescence image (Fig. 3a and Fig. 4a in the Supporting Information), both the blue FITC-BSA, [i.e., one form of alignment marker], reference line and the red patterned signals corresponding to protein secretion levels are readily visible, [i.e., plurality of images for analyte detection regions corresponding to the selected sample regions and associated analyte patterns]); “
an image processor that aligns associated images for selected sample retention regions using the at least one first alignment marker” (see at least: Page 13, Fig. 4, and Page 4, second paragraph, which shows the aligning associated images for selected sample retention regions using the at least one form alignment marker (FITC-BSA)); “(see Fig. 1, “single cell”), “and corresponding analyte patterns to discretely resolve released analytes associated with the retained at least one cell based on the analyte detection moieties detected in the analyte pattern” (Page 13, Fig. 4, and Page 4, second paragraph, “the blue FITC-BSA reference line and the red patterned signals corresponding to the ready visible protein secretion levels. Shown in the same figure are a bright field image of 14 microchambers with cells loaded, the corresponding fluorescent barcode image, and an overlay of the two”).
However, Lu does not provide a motivation to teach the ordered combination of “a plurality of second images having a different optical parameter than the first images, the second images for analyte detection regions corresponding to the selected sample regions and associated analyte patterns and additionally at least one second alignment marker” and the processor “further aligns images for analyte detection regions with corresponding images for selected sample retention regions using the at least one second alignment marker” in relations to the rest of the limitations in the claim. Dependent Claims 12-27 are not rejected over prior art, as they depend from the allowable independent Claim 11, and inherently include the above-described allowable subject matter.
Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance”.
Conclusion and Contact
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Siamak HARANDI whose telephone number is (571)270-1832. The examiner can normally be reached Monday - Friday 9:30 - 6:00 ET.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amandeep Saini can be reached on (571)272-3382. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Siamak Harandi/Primary Examiner, Art Unit 2662